                         SEQUENCE LISTING

<110>  ADC Therapeutics SA
       Medimmune Limited
 
<120>  COMBINATION THERAPY

<130>  007736226

<150>  GB 1917254.3
<151>  2019-11-27

<160>  57    

<170>  PatentIn version 3.5

<210>  1
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  AB12 VH

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr 
            20                  25                  30          


Ile Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Ile Pro Ile Leu Gly Val Glu Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Asp Trp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125         


<210>  2
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  AB12 VL

<400>  2

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro 
        115                 


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH CDR1

<400>  3

Arg Tyr Ile Ile Asn 
1               5   


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH CDR2

<400>  4

Arg Ile Ile Pro Ile Leu Gly Val Glu Asn Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  5
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH CDR3

<400>  5

Lys Asp Trp Phe Asp Tyr 
1               5       


<210>  6
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR1

<400>  6

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR2

<400>  7

Gly Ala Ser Ser Arg Ala Thr 
1               5           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR3

<400>  8

Gln Gln Tyr Gly Ser Ser Pro Leu Thr 
1               5                   


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Camrelizumab

<400>  9

Phe Ser Glu Ser Thr Asn Ser 
1               5           


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Camrelizumab

<400>  10

Ser Asn Thr Ser Glu Ser Phe 
1               5           


<210>  11
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Camrelizumab

<400>  11

Phe Arg Val Thr Gln Leu Ala Pro Lys Ala Gln Ile Lys Gln 
1               5                   10                  


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Camrelizumab

<400>  12

Ser Asn Thr Ser Glu Ser Phe 
1               5           


<210>  13
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Camrelizumab

<400>  13

Ser Asn Thr Ser Glu Ser Phe Lys Phe Arg Val Thr Gln Leu Ala Pro 
1               5                   10                  15      


Lys Ala Gln Ile Lys Glu 
            20          


<210>  14
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559/MDS-1105 (VH CDR1)

<400>  14

Asp Tyr Gly Phe Ser 
1               5   


<210>  15
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559/MDS-1105 (VH CDR2)

<400>  15

Trp Ile Thr Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln 
1               5                   10                  15      


Gly 
    


<210>  16
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559/MDS-1105 (VH CDR3)

<400>  16

Asp Tyr Phe Tyr Gly Met Asp Val 
1               5               


<210>  17
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559/MDS-1105 (VL CDR1)

<400>  17

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Val 
1               5                   10      


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559/MDS-1105 (VL CDR2)

<400>  18

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  19
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559/MDS-1105 (VL CDR3)

<400>  19

Gln Gln Arg Ser Asn Trp Pro Arg Thr 
1               5                   


<210>  20
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VH CDR1)

<400>  20

Thr Tyr Ala Ile Ser 
1               5   


<210>  21
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VH CDR2)

<400>  21

Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  22
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VH CDR3)

<400>  22

Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val 
1               5                   10                  


<210>  23
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VL CDR1)

<400>  23

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  24
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VL CDR3)

<400>  24

Gln Gln Arg Ser Asn Trp Pro Thr 
1               5               


<210>  25
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VH CDR1)

<400>  25

Ser Tyr Asp Val His 
1               5   


<210>  26
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VH CDR2)

<400>  26

Trp Leu His Ala Asp Thr Gly Ile Thr Lys Phe Ser Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  27
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VH CDR3)

<400>  27

Glu Arg Ile Gln Leu Trp Phe Asp Tyr 
1               5                   


<210>  28
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VL CDR1)

<400>  28

Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala 
1               5                   10      


<210>  29
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VL CDR2)

<400>  29

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  30
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMS-936559 / MDX-1105 (VL CDR3)

<400>  30

Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr 
1               5                   


<210>  31
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  durvalumab/MEDI4736 (VH)

<400>  31

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  32
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  durvalumab/MEDI4736 (VL)

<400>  32

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  33
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRX518, a humanized agylcosylated (Fc disabled) IgG1 anti-GITR 
       mAb (VL)

<400>  33

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Thr Asp Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  34
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRX518, a humanized agylcosylated (Fc disabled) IgG1 anti-GITR 
       mAb (VH)

<400>  34

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
        35                  40                  45              


Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 
65                  70                  75                  80  


Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Thr Arg Arg Tyr Phe Pro Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser 
        115             


<210>  35
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRX518, a humanized agylcosylated (Fc disabled) IgG1 anti-GITR 
       mAb (VH)

<400>  35

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
        35                  40                  45              


Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Gln Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 
65                  70                  75                  80  


Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Thr Arg Arg Tyr Phe Pro Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser 
        115             


<210>  36
<211>  450
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MEDI0562 (aka Tavolixizumab, Tavolimab) (HC)

<400>  36

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Ser Gly 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Lys His Pro Gly Lys Gly Leu Glu Tyr Ile 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Asn Gly Ile Thr Tyr His Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Ile Thr Ile Asn Arg Asp Thr Ser Lys Asn Gln Tyr Ser Leu 
65                  70                  75                  80  


Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Lys Tyr Asp Tyr Asp Gly Gly His Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 
    210                 215                 220                 


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
225                 230                 235                 240 


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
                245                 250                 255     


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
            260                 265                 270         


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
        275                 280                 285             


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
    290                 295                 300                 


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
305                 310                 315                 320 


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
                325                 330                 335     


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
            340                 345                 350         


Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 
        355                 360                 365             


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
    370                 375                 380                 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
385                 390                 395                 400 


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
                405                 410                 415     


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
            420                 425                 430         


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 
        435                 440                 445             


Pro Gly 
    450 


<210>  37
<211>  210
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MEDI0562 (aka Tavolixizumab, Tavolimab) (LC)

<400>  37

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Lys Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ala Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn 
    210 


<210>  38
<211>  402
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MEDI6383 (Efizonerimod alfa)

<400>  38

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 
1               5                   10                  15      


Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 
            20                  25                  30          


Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 
        35                  40                  45              


Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 
    50                  55                  60                  


Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 
65                  70                  75                  80  


Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 
                85                  90                  95      


Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 
            100                 105                 110         


Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 
        115                 120                 125             


Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 
    130                 135                 140                 


Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 
145                 150                 155                 160 


Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 
                165                 170                 175     


Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 
            180                 185                 190         


Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 
        195                 200                 205             


Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 
    210                 215                 220                 


Leu Ser Leu Gly Lys Asp Gln Asp Lys Ile Glu Ala Leu Ser Ser Lys 
225                 230                 235                 240 


Val Gln Gln Leu Glu Arg Ser Ile Gly Leu Lys Asp Leu Ala Met Ala 
                245                 250                 255     


Asp Leu Glu Gln Lys Val Leu Glu Met Glu Ala Ser Thr Gln Val Ser 
            260                 265                 270         


His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu Tyr 
        275                 280                 285             


Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile 
    290                 295                 300                 


Met Lys Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr 
305                 310                 315                 320 


Leu Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser Leu 
                325                 330                 335     


His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val Arg 
            340                 345                 350         


Ser Val Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys Val 
        355                 360                 365             


Tyr Leu Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His Val 
    370                 375                 380                 


Asn Gly Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe Cys 
385                 390                 395                 400 


Val Leu 
        


<210>  39
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OX40mAb24 (9B12) VH

<400>  39

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Ser Gly 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Lys His Pro Gly Lys Gly Leu Glu Tyr Ile 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Asn Gly Ile Thr Tyr His Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Ile Thr Ile Asn Arg Asp Thr Ser Lys Asn Gln Tyr Ser Leu 
65                  70                  75                  80  


Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Lys Tyr Asp Tyr Asp Gly Gly His Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  40
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OX40mAb24 (9B12) VL

<400>  40

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Lys Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ala Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  41
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VH CDR1

<400>  41

Gly Ser Ala Met His 
1               5   


<210>  42
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VH CDR2

<400>  42

Arg Ile Arg Ser Lys Ala Asn Ser Tyr Ala Thr Ala Tyr Ala Ala Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  43
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VH CDR3

<400>  43

Gly Ile Tyr Asp Ser Ser Gly Tyr Asp Tyr 
1               5                   10  


<210>  44
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VL CDR1

<400>  44

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 
1               5                   10                  15      


<210>  45
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VL CDR2

<400>  45

Leu Gly Ser Asn Arg Ala Ser 
1               5           


<210>  46
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VL CDR3

<400>  46

Met Gln Ala Leu Gln Thr Pro Leu Thr 
1               5                   


<210>  47
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VH

<400>  47

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Ser 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Gly Arg Ile Arg Ser Lys Ala Asn Ser Tyr Ala Thr Ala Tyr Ala Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ser Gly Ile Tyr Asp Ser Ser Gly Tyr Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  48
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  INCAGN1949 VL

<400>  48

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
                85                  90                  95      


Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  49
<211>  167
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tremelimumab  VH

<400>  49

Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser 
1               5                   10                  15      


Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro 
            20                  25                  30          


Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn 
        35                  40                  45              


Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp 
    50                  55                  60                  


Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu 
65                  70                  75                  80  


Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Arg Gly Ala Thr Leu 
                85                  90                  95      


Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val 
            100                 105                 110         


Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125             


Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu 
    130                 135                 140                 


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
145                 150                 155                 160 


Ala Leu Thr Ser Gly Val His 
                165         


<210>  50
<211>  139
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tremelimumab  VL

<400>  50

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys 
1               5                   10                  15      


Arg Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asp Trp Tyr Gln Gln Lys 
            20                  25                  30          


Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 
        35                  40                  45              


Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 
    50                  55                  60                  


Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr 
65                  70                  75                  80  


Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys 
                85                  90                  95      


Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro 
            100                 105                 110         


Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 
        115                 120                 125             


Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val 
    130                 135                 


<210>  51
<211>  223
<212>  PRT
<213>  Homo sapiens CTLA4 GenBank: AAL07473.1

<400>  51

Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala 
1               5                   10                  15      


Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro 
            20                  25                  30          


Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala 
        35                  40                  45              


Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly 
    50                  55                  60                  


Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln 
65                  70                  75                  80  


Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr 
                85                  90                  95      


Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val 
            100                 105                 110         


Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile 
        115                 120                 125             


Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly 
    130                 135                 140                 


Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 
145                 150                 155                 160 


Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe 
                165                 170                 175     


Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys 
            180                 185                 190         


Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu 
        195                 200                 205             


Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 
    210                 215                 220             


<210>  52
<211>  2025
<212>  DNA
<213>  Homo sapiens CTLA4 (CTLA4) mRNA, complete cds GenBank: AF414120.1

<400>  52
cttctgtgtg tgcacatgtg taatacatat ctgggatcaa agctatctat ataaagtcct       60

tgattctgtg tgggttcaaa cacatttcaa agcttcagga tcctgaaagg ttttgctcta      120

cttcctgaag acctgaacac cgctcccata aagccatggc ttgccttgga tttcagcggc      180

acaaggctca gctgaacctg gctaccagga cctggccctg cactctcctg ttttttcttc      240

tcttcatccc tgtcttctgc aaagcaatgc acgtggccca gcctgctgtg gtactggcca      300

gcagccgagg catcgccagc tttgtgtgtg agtatgcatc tccaggcaaa gccactgagg      360

tccgggtgac agtgcttcgg caggctgaca gccaggtgac tgaagtctgt gcggcaacct      420

acatgatggg gaatgagttg accttcctag atgattccat ctgcacgggc acctccagtg      480

gaaatcaagt gaacctcact atccaaggac tgagggccat ggacacggga ctctacatct      540

gcaaggtgga gctcatgtac ccaccgccat actacctggg cataggcaac ggaacccaga      600

tttatgtaat tgatccagaa ccgtgcccag attctgactt cctcctctgg atccttgcag      660

cagttagttc ggggttgttt ttttatagct ttctcctcac agctgtttct ttgagcaaaa      720

tgctaaagaa aagaagccct cttacaacag gggtctatgt gaaaatgccc ccaacagagc      780

cagaatgtga aaagcaattt cagccttatt ttattcccat caattgagaa accattatga      840

agaagagagt ccatatttca atttccaaga gctgaggcaa ttctaacttt tttgctatcc      900

agctattttt atttgtttgt gcatttgggg ggaattcatc tctctttaat ataaagttgg      960

atgcggaacc caaattacgt gtactacaat ttaaagcaaa ggagtagaaa gacagagctg     1020

ggatgtttct gtcacatcag ctccactttc agtgaaagca tcacttggga ttaatatggg     1080

gatgcagcat tatgatgtgg gtcaaggaat taagttaggg aatggcacag cccaaagaag     1140

gaaaaggcag ggagcgaggg agaagactat attgtacaca ccttatattt acgtatgaga     1200

cgtttatagc cgaaatgatc ttttcaagtt aaattttatg ccttttattt cttaaacaaa     1260

tgtatgatta catcaaggct tcaaaaatac tcacatggct atgttttagc cagtgatgct     1320

aaaggttgta ttgcatatat acatatatat atatatatat atatatatat atatatatat     1380

atatatatat tttaatttga tagtattgtg catagagcca cgtatgtttt tgtgtatttg     1440

ttaatggttt gaatataaac actatatggc agtgtctttc caccttgggt cccagggaag     1500

ttttgtggag gagctcagga cactaataca ccaggtagaa cacaaggtca tttgctaact     1560

agcttggaaa ctggatgagg tcatagcagt gcttgattgc gtggaattgt gctgagttgg     1620

tgttgacatg tgctttgggg cttttacacc agttcctttc aatggtttgc aaggaagcca     1680

cagctggtgg tatctgagtt gacttgacag aacactgtct tgaagacaat ggcttactcc     1740

aggagaccca caggtatgac cttctaggaa gctccagttc gatgggccca attcttacaa     1800

acatgtggtt aatgccatgg acagaagaag gcagcaggtg gcagaatggg gtgcatgaag     1860

gtttctgaaa attaacactg cttgtgtttt taactcaata ttttccatga aaatgcaaca     1920

acatgtataa tatttttaat taaataaaaa tctgtggtgg tcgttttaaa aaaaaaaaaa     1980

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa                     2025


<210>  53
<211>  223
<212>  PRT
<213>  Homo sapiens Cytotoxic T-lymphocyte protein 4 UniProt: P16410

<400>  53

Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala 
1               5                   10                  15      


Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro 
            20                  25                  30          


Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala 
        35                  40                  45              


Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly 
    50                  55                  60                  


Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln 
65                  70                  75                  80  


Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr 
                85                  90                  95      


Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val 
            100                 105                 110         


Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile 
        115                 120                 125             


Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly 
    130                 135                 140                 


Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 
145                 150                 155                 160 


Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe 
                165                 170                 175     


Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys 
            180                 185                 190         


Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu 
        195                 200                 205             


Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 
    210                 215                 220             


<210>  54
<211>  241
<212>  PRT
<213>  Homo sapiens glucocorticoid-induced TNFR-related protein GenBank: AAD22635.1

<400>  54

Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu 
1               5                   10                  15      


Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro 
            20                  25                  30          


Gly Cys Gly Pro Gly Arg Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg 
        35                  40                  45              


Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu 
    50                  55                  60                  


Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His 
65                  70                  75                  80  


Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro 
                85                  90                  95      


Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys 
            100                 105                 110         


Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys 
        115                 120                 125             


Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro 
    130                 135                 140                 


Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala 
145                 150                 155                 160 


Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys 
                165                 170                 175     


Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu 
            180                 185                 190         


Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val 
        195                 200                 205             


Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu 
    210                 215                 220                 


Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp 
225                 230                 235                 240 


Val 
    


<210>  55
<211>  241
<212>  PRT
<213>  Homo sapiens TNR18_HUMAN Tumor necrosis factor receptor superfamily member 18 UniProt: Q9Y5U5

<400>  55

Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu 
1               5                   10                  15      


Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro 
            20                  25                  30          


Gly Cys Gly Pro Gly Arg Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg 
        35                  40                  45              


Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu 
    50                  55                  60                  


Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His 
65                  70                  75                  80  


Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro 
                85                  90                  95      


Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys 
            100                 105                 110         


Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys 
        115                 120                 125             


Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro 
    130                 135                 140                 


Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala 
145                 150                 155                 160 


Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys 
                165                 170                 175     


Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu 
            180                 185                 190         


Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val 
        195                 200                 205             


Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu 
    210                 215                 220                 


Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp 
225                 230                 235                 240 


Val 
    


<210>  56
<211>  277
<212>  PRT
<213>  Homo sapiens OX40 homologue GenBank: CAA53576.1

<400>  56

Met Cys Val Gly Ala Arg Arg Leu Gly Arg Gly Pro Cys Ala Ala Leu 
1               5                   10                  15      


Leu Leu Leu Gly Leu Gly Leu Ser Thr Val Thr Gly Leu His Cys Val 
            20                  25                  30          


Gly Asp Thr Tyr Pro Ser Asn Asp Arg Cys Cys His Glu Cys Arg Pro 
        35                  40                  45              


Gly Asn Gly Met Val Ser Arg Cys Ser Arg Ser Gln Asn Thr Val Cys 
    50                  55                  60                  


Arg Pro Cys Gly Pro Gly Phe Tyr Asn Asp Val Val Ser Ser Lys Pro 
65                  70                  75                  80  


Cys Lys Pro Cys Thr Trp Cys Asn Leu Arg Ser Gly Ser Glu Arg Lys 
                85                  90                  95      


Gln Leu Cys Thr Ala Thr Gln Asp Thr Val Cys Arg Cys Arg Ala Gly 
            100                 105                 110         


Thr Gln Pro Leu Asp Ser Tyr Lys Pro Gly Val Asp Cys Ala Pro Cys 
        115                 120                 125             


Pro Pro Gly His Phe Ser Pro Gly Asp Asn Gln Ala Cys Lys Pro Trp 
    130                 135                 140                 


Thr Asn Cys Thr Leu Ala Gly Lys His Thr Leu Gln Pro Ala Ser Asn 
145                 150                 155                 160 


Ser Ser Asp Ala Ile Cys Glu Asp Arg Asp Pro Pro Ala Thr Gln Pro 
                165                 170                 175     


Gln Glu Thr Gln Gly Pro Pro Ala Arg Pro Ile Thr Val Gln Pro Thr 
            180                 185                 190         


Glu Ala Trp Pro Arg Thr Ser Gln Gly Pro Ser Thr Arg Pro Val Glu 
        195                 200                 205             


Val Pro Gly Gly Arg Ala Val Ala Ala Ile Leu Gly Leu Gly Leu Val 
    210                 215                 220                 


Leu Gly Leu Leu Gly Pro Leu Ala Ile Leu Leu Ala Leu Tyr Leu Leu 
225                 230                 235                 240 


Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly 
                245                 250                 255     


Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser 
            260                 265                 270         


Thr Leu Ala Lys Ile 
        275         


<210>  57
<211>  277
<212>  PRT
<213>  Homo sapiens TNR4_HUMAN Tumor necrosis factor receptor superfamily member 4 UniProt: P43489

<400>  57

Met Cys Val Gly Ala Arg Arg Leu Gly Arg Gly Pro Cys Ala Ala Leu 
1               5                   10                  15      


Leu Leu Leu Gly Leu Gly Leu Ser Thr Val Thr Gly Leu His Cys Val 
            20                  25                  30          


Gly Asp Thr Tyr Pro Ser Asn Asp Arg Cys Cys His Glu Cys Arg Pro 
        35                  40                  45              


Gly Asn Gly Met Val Ser Arg Cys Ser Arg Ser Gln Asn Thr Val Cys 
    50                  55                  60                  


Arg Pro Cys Gly Pro Gly Phe Tyr Asn Asp Val Val Ser Ser Lys Pro 
65                  70                  75                  80  


Cys Lys Pro Cys Thr Trp Cys Asn Leu Arg Ser Gly Ser Glu Arg Lys 
                85                  90                  95      


Gln Leu Cys Thr Ala Thr Gln Asp Thr Val Cys Arg Cys Arg Ala Gly 
            100                 105                 110         


Thr Gln Pro Leu Asp Ser Tyr Lys Pro Gly Val Asp Cys Ala Pro Cys 
        115                 120                 125             


Pro Pro Gly His Phe Ser Pro Gly Asp Asn Gln Ala Cys Lys Pro Trp 
    130                 135                 140                 


Thr Asn Cys Thr Leu Ala Gly Lys His Thr Leu Gln Pro Ala Ser Asn 
145                 150                 155                 160 


Ser Ser Asp Ala Ile Cys Glu Asp Arg Asp Pro Pro Ala Thr Gln Pro 
                165                 170                 175     


Gln Glu Thr Gln Gly Pro Pro Ala Arg Pro Ile Thr Val Gln Pro Thr 
            180                 185                 190         


Glu Ala Trp Pro Arg Thr Ser Gln Gly Pro Ser Thr Arg Pro Val Glu 
        195                 200                 205             


Val Pro Gly Gly Arg Ala Val Ala Ala Ile Leu Gly Leu Gly Leu Val 
    210                 215                 220                 


Leu Gly Leu Leu Gly Pro Leu Ala Ile Leu Leu Ala Leu Tyr Leu Leu 
225                 230                 235                 240 


Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly 
                245                 250                 255     


Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser 
            260                 265                 270         


Thr Leu Ala Lys Ile 
        275         


